Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06399146
Other study ID # JZimmer
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date October 1, 2024

Study information

Verified date May 2024
Source Hillerod Hospital, Denmark
Contact Julie Zimmer, stud.med
Phone +4795102393
Email juzim@online.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to test a novel smartphone application, Picterus, which provides a cheaper, patient-friendly, and more readily means of neonatal jaundice detection. For this purpose, the study aims to collect data from newborns with a broad range of bilirubin levels and high melanin content in a population in Botswana.


Description:

Neonatal jaundice is a condition in newborns with elevated levels of the waste product bilirubin, also known as hyperbilirubinemia. It is primarily caused by a combination of the rapid turnover of red blood cells and the immature liver functions in the newborn. Neonatal jaundice affects approximately 60 to 80 % of newborns but is usually self-limiting and harmless. The condition is still potentially dangerous because bilirubin can accumulate in the basal ganglia of the brain, where it can cause permanent brain damage. Such brain damage, better known as kernicterus, can manifest as cerebral palsy, deafness, language difficulty, or in the worst cases, be fatal. This study will be conducted at a hospital in Botswana, where the study aim to collect data from newborns with a broad range of bilirubin levels and high melanin content. The investigators hypothesize that the Picterus JP will offer bilirubin level estimates that are highly correlated to bilirubin levels measured in blood samples in a population in Botswana. Following our hypothesis, the short-term goal for this project is to demonstrate that this screening method can be used to identify children with severe neonatal jaundice independent of skin color. Thus, providing a cheaper, patient-friendly, and more readily available means of neonatal jaundice detection. The study will be a diagnostic accuracy cross-sectional study with quantitative methods of data collection. The study population will comprise 150 newborns from the Neonatal Unit and the postnatal ward at Princess Marina Hospital, a number determined by a sample size calculation based on standard errors of the 95% limit agreement, as described by Bland and Alman. The study objective of this study is two-folded. First, to determine the correlation between TSB measurement and Picterus image estimate of serum-bilirubin. Second, to determine the accuracy of the Picterus App used as a screening tool. Following informed consent, background data such as birth weight, age on examination, gestational age, and type of feeding will be obtained. The skin type of the infant will be classified according to the newborn Neomar's scale score. Transcutaneous bilirubin estimates will be performed over the sternum of the infant. A Dräger Jaundice Meter JM-105 will be used in this study. Skin reflectance will be done using a CE-marked portable Konica Minolta spectrophotometer CM-700d. The spectrophotometer readings will be used to adjust the existing algorithm from Picterus to African skin and thereafter bilirubin estimates from the taken images will be determined. The Picterus calibration card will be fixed in place with a disposable back sticker on the newborn's chest with the hole of the card placed over the infant's sternum. A validated smartphone with Picterus JP will then be used to collect digital images, as shown below. Once the phone is aligned with the card, two sets of 6 images of each newborn will be captured, 3 with flash and 3 without flash. After all the images are obtained, a unique ID will be displayed on the smartphone. This ID will be recorded on the case report forms and later used to pair clinical data and digital images. A blood sample to determine TSB will be obtained within 60 minutes of obtaining the images and processed at the Department of clinical biochemistry in the hospital laboratory. In addition, TSB will be measured with neonatal bilirubin analyzer Neo-Bil Plus from DAS to assess the quality of the equipment. For the hospital laboratory analysis, 1 ml of blood is required and will be obtained either by venous puncture or heel prick. An additional 10 μl volume of blood will be collected in a heparinized capillary tube for analysis in the Neo-Bil Plus equipment. The bilirubin estimates from the images taken will be determined. The images will be compared to the TSB, NeoBil and TcB measurements using the Pearson correlation coefficient. Sub-analysis for the different skin colors, gestational ages, days of life, and bilirubin levels will be performed for the TSB and image estimate. Sensitivity and specificity analysis will be calculated for different cut-off values using the ROC analysis. Systematic over- or under-estimation of bilirubin levels will be evaluated using Bland-Altman plots. To avoid bias, the developer of the product - Picterus AS - will not be involved in statistical work-up or even see the raw data. The results from this study will have relevance for the potential validation of the innovation. Studies demonstrating the tool's potential in a high-burden setting will be necessary for users of the device. This is the first validation study following the study in Uganda. The results of this study will result in a published paper in a peer-reviewed journal. Further, the study's results will be communicated through popular media and seminars in both countries.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date October 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 24 Hours to 14 Days
Eligibility Inclusion Criteria: - Gestational age > 37 weeks - Birth weight > 2000 g and < 4500 g - Age > 24 hours and < 14 days - Infants requiring a blood sample for clinically suspected jaundice or other screening Exclusion Criteria: - Infants transferred to the pediatric ward for advanced treatment - Infants with a skin rash or other disease that affects the skin where measurements are performed - Infants that receive or have received phototherapy in the last 24 hours - Infants with an inborn disease

Study Design


Intervention

Device:
Picterus App
Take a photo off the patient's skin (sternum).

Locations

Country Name City State
Botswana Princess Marina Hospital Gaborone

Sponsors (2)

Lead Sponsor Collaborator
Hillerod Hospital, Denmark Picterus AS

Country where clinical trial is conducted

Botswana, 

Outcome

Type Measure Description Time frame Safety issue
Primary Picterus app estimate Estimate of total serum bilirubin in the blood by a smartphone app Must be performed within 1 hour of blood sample
Primary Total serum bilirubin Total serum bilirubin determined by a blood sample Must be performed within 1 hour of measurement with smartphone app and transcutaneous bilirubinometer
Secondary Transcutaneous bilirubin Estimate of total serum bilirubin in the blood by a transcuteous bilirubinometer. Must be performed within 1 hour of blood sample
See also
  Status Clinical Trial Phase
Recruiting NCT04365998 - BUBOLight®, a New Phototherapy Device for the Treatment of the Newborn's Jaundice N/A
Completed NCT02222805 - Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment N/A
Completed NCT01622699 - Implementation of a Transcutaneous Bilirubinometer N/A
Completed NCT00692224 - Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial Phase 1/Phase 2
Not yet recruiting NCT06080971 - Persistent Neonatal Jaundice on Neonates and Childern
Recruiting NCT06075290 - the Difference of Follow-up Methods of Neonatal Jaundice
Recruiting NCT05955144 - Clinical Validation of the Screening Tool Picterus JP Using Different Smartphones N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Completed NCT03306004 - Neonatal Jaundice: Knowledge, Attitudes and Practices of Mothers and Medical Trainees and Providers in and Around Ogbomosho N/A
Completed NCT02774434 - Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age N/A
Terminated NCT05365399 - Evaluation of a Smartphone-based Screening Tool for Neonatal Jaundice in a Ugandan Population N/A
Recruiting NCT03933423 - Home Based Phototherapy for Neonatal Jaundice N/A
Recruiting NCT06087874 - Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice Phase 2
Recruiting NCT03183986 - Comparison of the Efficacy of Phototherapy Using Blue LED's With Wavelength 478 vs. 459 nm. N/A
Withdrawn NCT00917007 - Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
Completed NCT06227624 - Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia Phase 3
Completed NCT04433923 - Aluminium Foil as an Adjuvant to Phototherapy for Pathological Unconjugated Hyperbilirubinaemia in Full Term Infants N/A
Completed NCT04418180 - Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants N/A
Completed NCT06386731 - Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice N/A
Not yet recruiting NCT05475223 - End Tidal Carbon Monoxide (ETCO): - A Tool to Aid Identification of Neonatal Hemolysis N/A